Abstract: Objective: To find out the advantages of adding recombinant human epidermal growth factor on the basis of Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) for the treatment of diabetic difficult-to-heal skin ulcers. Methods: 98 cases of diabetic skin ulcers were studied, and the patients were randomly divided into the control group (Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment)) and the experimental group (Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with recombinant human epidermal growth factor) by coin tossing method, comparing the statistical differences in ulcerated area and quality of life of the patients in the two groups before and after the treatment (7 d), comparing the statistically significant differences in the time of muscle growth, average healing time, number of dressing changes, and clinical efficacy of the patients in the two groups. We also compared the time of muscle growth, average healing time, number of dressing changes, and clinical efficacy of the two groups. Results: After treatment, the ulcerated area of patients in the experimental group was significantly lower than that of patients in the control group, and the quality of life score of patients in the experimental group was significantly higher than that of patients in the control group, with statistically significant differences (P<0.05); the average time of muscle growth, average healing time and number of dressing changes of patients in the experimental group were significantly lower than that of patients in the control group, with statistically significant differences (P<0.05); clinical efficacy of the patients in both groups was also compared, with the number of cured patients in the experimental group significantly lower than that of patients in the control group, and the number of cured patients in the experimental group was significantly lower than that of patients in the control group. Comparing the clinical efficacy of the two groups, the number of patients cured in the experimental group was significantly higher than that in the control group, and the difference was statistically significant (Z=7.030, P=0.030). Conclusion: On the basis of Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) for the treatment of diabetic difficult-to-heal skin ulcers, the addition of recombinant human epidermal growth factor can help to accelerate the healing of ulcers and improve the therapeutic effect.
YANG De-Yong, CAI Xue-Tao, LI Jie-Hua, PI Xiao-Bing, DONG Dong, HE Xiao-Liang, QIN Jun. Therapeutic effect of Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with recombinant human epidermal growth factor in the treatment of diabetic skin ulcers that are difficult to heal[J]. Jilin Medical Science, 2021, 42 (05): 1053-1056.